Overview
Cat #:
ANR-212
Alternative Name Prostaglandin F2 Receptor Inhibitor, CD9 Partner 1, CD9P-1, FPRP, Glu-Trp-Ile EWI motif-containing protein F, EWI-F, CD315
Lyophilized Powder yes
Type: Polyclonal
Host: Rabbit
Reactivity: h, m, r
ImmunogenPeptide (C)EDEFRYRMYQTQVSD, corresponding to amino acid residues 635 - 649 of mouse PTGFRN (Accession
Q9WV91). Extracellular, N-terminus.
Accession (Uniprot) Number Q9WV91
Gene ID 19221
Peptide confirmation Confirmed by amino acid analysis and mass spectrometry.
Homology Rat – identical. Human – 14 out of 15 amino acid identical.
Purity Affinity purified on immobilized antigen.
Form Lyophilized powder. Reconstituted antibody contains phosphate buffered saline (PBS), pH 7.4, 1% BSA, 0.05% NaN3.
Form Lyophilized powder. Reconstituted antibody contains phosphate buffered saline (PBS), pH 7.4.
Isotype Rabbit IgG.
Storage before reconstitution The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C.
Reconstitution 25 µl, 50 µl or 0.2 ml double distilled water (DDW), depending on the sample size.
Reconstitution 0.2 ml double distilled water (DDW).
Antibody concentration after reconstitution 0.8 mg/ml.
Antibody concentration after reconstitution 1 mg/ml.
Storage after reconstitution The reconstituted solution can be stored at 4°C for up to 1 week. For longer periods, small aliquots should be stored at -20°C. Avoid multiple freezing and thawing. Centrifuge all antibody preparations before use (10000 x g 5 min).
Preadsorption Control 2 µg peptide per 1 µg antibody
PTGFRN (extracellular) Blocking Peptide (#BLP-NR212) Standard quality control of each lot Western blot analysis.
Applications: ifc, ih, lci, wb
Scientific background The Prostaglandin F2 Receptor Negative Regulator (PTGFRN), also known as EWI-F and CD9P-1, is a member of the immunoglobulin (Ig) superfamily. PTGFRN is a type I single-pass transmembrane protein and part of the cell adhesion molecule (CAM) family, which plays essential roles in cell-cell and cell-matrix interactions1,2.
CAMs, including PTGFRN, are characterized by extracellular Ig-like domains and contribute to cellular adhesion, migration, and signaling. PTGFRN interacts with tetraspanins (CD9, CD81), integrins, and ERM proteins, functioning as a scaffold in tetraspanin-enriched microdomains (TEMs)3. These interactions enable its role in tumor progression, metastasis, and angiogenesis by regulating PI3K/AKT and mTOR signaling pathways1,2.
PTGFRN is highly expressed in glioblastoma (GBM) and several cancers, with significantly elevated levels in tumor tissues compared to normal tissues1,2,3. It is implicated in tumor proliferation, migration, and radiation resistance. In neurodegenerative disorders, PTGFRN correlates with Alzheimer’s disease progression via its role in extracellular vesicles (EVs) associated with amyloid plaques3.
PTGFRN’s association with poor prognosis in cancers and its involvement in neurodegeneration highlight its potential as a therapeutic target. Immunodetection of PTGFRN can benefit research areas in oncology, neurobiology, and regenerative medicine1,2,4.
Lyophilized Powder
For research purposes only, not for human use
Last Update: 19/12/2024
